Retatrutide + Cagrilintide 12.5/2.5 mg

Retatrutide + Cagrilintide for research: identity and specifications

Retatrutide + Cagrilintide is a co-formulated blend of two synthetic peptides in a single vial: retatrutide (CAS 2381089-83-2), studied as a triple agonist of the GIP, GLP-1 and glucagon receptors, and cagrilintide (CAS 1415456-99-3), a long-acting amylin analog. Supplied as a vial with 12.5 mg of retatrutide and 2.5 mg of cagrilintide, lyophilized powder, with no fillers, carriers or excipients, at ≥98% purity by HPLC, made by SPPS and purified under analytical controls.

Scientific background

Retatrutide is investigated in experimental models for simultaneous agonism of the GIP, GLP-1 and glucagon receptors, with a focus on cAMP signaling and the interplay among the three receptors. Cagrilintide, in turn, is an amylin analog studied for activation of amylin and calcitonin receptors in cell-based assays.

In laboratory settings, the combination is examined for overlap between incretin and amylin signaling pathways and for receptor co-agonism, in cell culture and rodent models, always under controlled bench conditions and without extrapolating results to human or veterinary use.

• GIP, GLP-1 and glucagon receptor agonism in cell-based assays
• Amylin and calcitonin receptor activation in vitro
• Overlap of incretin and amylin pathways
• Receptor co-agonism in experimental models

Technical specifications

Analytical quality and chain of custody

Every lot of Retatrutide + Cagrilintide is synthesized in registered facilities, with independent analytical verification by third-party laboratories and full chain-of-custody documentation. The certificate of analysis (COA) for each lot can be reviewed before purchase, recording HPLC purity and the other quality-control parameters used to release the material.

Reconstitution and laboratory handling

As a bench procedure, the lyophilized vial is reconstituted with a known volume of a suitable solvent, added along the inner wall of the vial, followed by gentle swirling until fully dissolved, without vigorous shaking. The reconstituted solution should be kept refrigerated and protected from light, and used in controlled assays within the stability period validated by the laboratory. Handling must be performed only by qualified personnel, in a bench environment suitable for in vitro experimentation, with lot number and storage conditions documented according to good laboratory practice.

Frequently asked questions

What is the purity of the blend supplied?

≥98% by HPLC, with the lot-specific value reported on the certificate of analysis (COA).

What are the components of the blend and in what ratio?

Retatrutide (PubChem CID 171390338) and cagrilintide (PubChem CID 171397054), supplied at 12.5 mg + 2.5 mg per vial.

How should the blend be stored?

At -20 °C, protected from light and moisture, as a lyophilized powder until reconstitution.

Does the certificate of analysis come with the lot?

Yes, every lot has a matching COA that can be verified before purchase using the button on this page.

Who can purchase Retatrutide + Cagrilintide?

Sales are restricted to qualified researchers and institutions, for laboratory use only, as detailed in the research-use-only notice on this page.

See the peptide reference guide, the page on how every lot is tested by HPLC and COA and the molecular structures in PubChem: Retatrutide and Cagrilintide.

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition. Sales are restricted to researchers and institutions.